Blog

February 27, 2024

Aizon Appoints Scott B. Waldman to Board of Directors

San Francisco, CA. – February 27, 2024 –  Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, today announced the appointment of Scott B. Waldman to the Company’s Board of Directors (the “Board”), effective immediately. Mr. Waldman will serve as an Independent Director.

 

“I am pleased to welcome Mr. Waldman to Aizon’s Board of Directors, where he will play an integral role in supporting the execution of our strategy during this next pivotal phase of growth,” said Pep Gubau, Aizon CEO and co-founder. “Mr. Waldman brings a proven track record and valuable, hands-on experience advising companies through key moments of transformation and business development, and I am confident that his expertise and industry insights will strengthen our leadership and best position Aizon for the future. On behalf of the entire Board, we are looking forward to working alongside Scott as we continue to scale to support even more global customers.” 

Mr. Waldman has led and advised life sciences companies for more than 25 years. He is founder and managing member of Waldman Growth Strategies, a strategy, M&A and legal consulting firm that supports private equity firms and life sciences companies through transactions and corporate milestones, with a focus on pharma and biotech contract development and manufacturing (CDMOs) and life science research and manufacturing. Prior to Waldman Growth Strategies, Mr. Waldman served as senior vice president, head of corporate development at Curia Global, a global CDMO where he led the company’s expansion into biologics through acquisitions, as well as leading corporate strategy and commercial functions. Prior to that, he spent 10 years at Lonza as U.S. general counsel and then as chief strategy officer, where he led Lonza’s M&A strategy, including the transformational $5.5 billion acquisition of Capsugel, and was integral to developing the company’s growth strategy and implementing initiatives that drove profitability. Before Lonza, Mr. Waldman was general counsel for Enzon Pharmaceuticals. He began his career in law in New York, first at Sidley Austin and then at Weil, Gotshal & Manges.

 

“Aizon’s innovative solutions address the tremendous opportunity to digitize pharmaceutical manufacturers’ operations and unlock the full potential of their data by harnessing technology,” said Mr. Waldman. “While manufacturers have made great strides to streamline their processes, Aizon’s technology leverages AI to further enhance efficiency and quality, and I am confident that Aizon has the ability to further revolutionize the industry with the upcoming launch of its next-generation eBR solution. I am thrilled to join such an innovative and dynamic company, and look forward to working closely with the Board and leadership team to take Aizon to the next level.”

About Aizon

 

Aizon stands at the forefront of pharmaceutical manufacturing innovation with its advanced, GMP-compliant, predictive analytics platform, distinguished by its unique combination of industrialized AI and contextualized Historian. This powerful synergy and the platform’s flexibility enable Aizon to provide unparalleled insights and enhanced decision-making capabilities in Pharma Manufacturing. For more information, please visit aizon.ai.

 

Media Contacts:

 

Emma Prenn-Vasilakis

emma.prenn-vasilakis@h-advisors.global

917-763-6685

Lluis Solanes

lluis.solanes@aizon.ai

February 8, 2024

We’ve Secured $20M in Series C Funding to Boost Our Pharma Manufacturing Platform and Prepare for Next-Generation eBR Launch

Today marks a significant milestone for us at Aizon, as we’re thrilled to announce the successful closure of $20 million in Series C funding. This round, spearheaded by NewVale Capital, a growth equity fund renowned for its investment in service businesses that excel in pharmaceuticals and biotechnology, signals a new chapter in our journey. We’re also proud to have the continued backing from our existing investors, including Atlantic Bridge, Crosslink Capital, and Uncork Capital. This substantial investment not only underlines our leadership in AI-enhanced pharmaceutical manufacturing but also gears us up for a phase of accelerated growth and innovation.

At Aizon, we’re passionate about transforming pharmaceutical manufacturing operations with our Artificial Intelligence (AI) SaaS solutions. Our platform leverages the most advanced predictive analytics, artificial intelligence, and smart factory technologies, making it the most powerful and accessible GMP AI platform for pharmaceutical manufacturers. This enables our customers to unlock groundbreaking insights, enhance decision-making, discover new optimization paths, reduce costs, anticipate deviations, and elevate their manufacturing systems. Quality and compliance are at the core of our mission; we adhere to GAMP5 guidelines for GMP processes, ensuring compliant data management across acquisition, storage, and consumption.

The fresh infusion of capital is a testament to the potential and success of our platform, fueling our ambition to execute our strategic roadmap more effectively. “This investment is a cornerstone for our company’s future growth. It not only validates the success of our platform but also equips us to better realize our strategic objectives,” says Pep Gubau, our CEO and co-founder. “Thanks to this additional funding and the unwavering support from our partners, we’re setting sights on fast-tracking the debut of our groundbreaking eBR solution in Q3 2024. This innovation will revolutionize the industry, reinforcing our dedication to constantly enhancing our offerings and empowering our clients with the most advanced technologies.”

Pep Gubau, Aizon CEO

Pep Gubau, Aizon's CEO

Todd Holmes, managing partner at NewVale Capital, shares our enthusiasm: “We’re excited to contribute to this new chapter for Aizon, as it continues to redefine pharmaceutical manufacturing with its AI-driven solutions. Our investment focus is on companies like Aizon, which have a proven business model and offer significant value to their clients in the pharmaceutical space.”

About Us

Aizon is pioneering innovation in pharmaceutical manufacturing with our advanced, GMP-compliant predictive analytics platform. Our unique blend of industrialized AI and contextualized Historian data sets us apart, offering unmatched insights and improved decision-making in pharma manufacturing. To discover more about how we’re shaping the future, visit our website at http://www.aizon.ai.

About NewVale Capital

Established in 2022, NewVale Capital is a growth equity fund dedicated to fostering the next wave of Life Science services companies. The firm targets proven, revenue-generating service businesses across the Life Science ecosystem that play a crucial role in delivering medicines to patients. For more details, check out: http://www.newvalecapital.com.

August 29, 2023

Aizon: Recognized as a 2022 Roger F. Sherwood Article of the Year Award Finalist

We are thrilled to announce that Aizon has been selected as one of the finalists for the esteemed 2022 Roger F. Sherwood Article of the Year Award. This recognition comes from Pharmaceutical Engineering, a leading publication in the industry.

Among a competitive field of 36 feature and technical articles published in Pharmaceutical Engineering during the 2022 calendar year (Volume 42), Aizon’s article has stood out for its exceptional contribution to the field of pharmaceuticals.

The article, titled “Measuring Pharma’s Adoption of Industry 4.0,” co-authored by our CSO Toni Manzano and Agustí Canals, PhD, delves into the critical intersection of technology and pharmaceuticals. This acknowledgment underscores Aizon’s dedication to pushing the boundaries of innovation in the PharmaTech sector.

The Roger F. Sherwood Article of the Year Award, established by ISPE in 1993, is a testament to the pursuit of excellence in knowledge-sharing within the pharmaceutical industry. It not only showcases the best content in Pharmaceutical Engineering but also enhances industry recognition and upholds ISPE’s reputation as a global knowledge leader.

An esteemed subcommittee of the Pharmaceutical Engineering Committee (PEC) rigorously evaluated the articles based on their usefulness to ISPE readers, their impact on advancing key topics, and their clarity and ease of reading.

The winner of the 2022 Roger F. Sherwood Article of the Year Award will be unveiled shortly, and the authors of the winning article will be honored at the upcoming 2023 ISPE Annual Meeting & Expo in Las Vegas, Nevada, USA.

We extend our heartfelt congratulations to Toni Manzano and Agustí Canals for their exceptional work and contribution to the advancement of knowledge in the pharmaceutical domain. This recognition reinforces our commitment to excellence and innovation.

March 13, 2023

If your data could talk…

Data Understanding and Contextualization

Your drug manufacturing process produces thousands of data points, and the data comes from different systems and different formats. In addition to that, some of it is GMP data (FDA guidance), and some are not. Your processes are working to support the same outcome, but using the data to make improvements is nearly impossible if every system speaks a different language.

The answer isn’t just in aggregating data. The power comes from giving the data context and understanding it as it relates to everything else coming out of your systems.

First, consider data understanding in a different way: language translation.

If you have a French speaker and a Mandarin speaker, how do they communicate without losing anything in translation? Without a common language, we need the French speaker to translate to Mandarin or vice versa. The risk in that is losing intent, meaning, and context. To have a common understanding of the language, we need to do a few things:

  • Maintain original language so meaning and intent are kept. To do this, we have to keep the French language as only French and the Mandarin language as only Mandarin.
  • Layer on a translator that maintains the original intent, meaning, and context of the French or Mandarin speaker.
  • The translator delivers the same message and context in a language that both speakers understand.

The result: Without changing either language, we have created context and commonality by layering on a translator that can understand the intricacies of both languages.

Keeping it Compliant

Now, imagine this for GMP and non-GMP data and what that requires of your systems and processes. To use the data to make decisions, it has to be GxP compliant; however, how do you manage this if not every system is compliant (and it doesn’t need to be)? The answer is in the “translator.” 

Let’s take ERP and production data, for example. Your ERP system is not necessarily validated for a manufacturing process; however, the data going into and coming out of it could be relevant to understanding your manufacturing processes and the materials involved. You also have production data in batch records, and that data is required to be compliant. How do you find connections between the data to help you make decisions, and how do you make sure it stays compliant?

  • Use GxP compliant systems: This doesn’t mean validating your ERP system, it means getting your data into a platform that is GxP compliant and can easily be validated.
  • Aggregate your data: Getting your data into one, GxP compliant, data lake is a hugely important step, but it’s not enough. You’ll have your data in one place, but it’s still not speaking the same language.
  • Break data silos: This is where the magic starts to happen: data contextualization.

 

Data contextualization isn’t about changing data to give it meaning. It’s about having that “translator” that allows all data to be kept in its original format while giving it meaning with respect to the other data points coming out of your systems.

Let’s look at two examples of where data contextualization matters in a biopharma manufacturing environment:

  • CDMOs often manufacture products for more than one Sponsor at a time, and they want to understand how to make a process more efficient, but using data only from customer A. The same equipment could be used for Customer A and Customer B, but of course they have different processes, recipes, and products altogether. Without understanding the data output in the context of the batches developed for Customer A, how could they use it to make any improvements? Without automatic data contextualization, the answer is: manually. The time it takes to do this is prohibitive and is prone to errors. The better, compliant, and more efficient answer is: aggregating data into a GxP Compliant system where data context and understanding are automatic. It is a place where your data speaks a common language and is filtered and associated with other data for specific usages while following security and integrity needs.
  • Take lab data, chromatography specifically. You might do chromatography in different types of equipment, meaning that although the data is the same type, it is coming from different systems, and those systems don’t always produce the same type of files. All data coming from the chromatography process is “chromatography data,” holding great possibilities for data analytics. But it is not until the data is transformed (in a GxP compliant way) that this becomes possible.
With a platform like Aizon’s, where GxP compliance and contextualization are built in, our customers are getting immense value out of understanding their processes in context. Data analytics, process improvements, and ultimately manufacturing outcomes, are all made possible when your data starts speaking the same language.

June 23, 2022

Aizon Wins “Best AI-based Solution for Manufacturing” Award in 2022 Artificial Intelligence Breakthrough Awards Program

Prestigious International Annual Awards Program Honors Standout AI and Machine Learning Solutions and Companies

SAN FRANCISCO – June 23, 2022 – Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, today announced that it has been named “Best AI-based Solution for Manufacturing” in the fifth annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today.

Aizon’s platform leverages Industry 4.0 technologies including AI and machine learning (ML) to improve manufacturing operations for the biopharmaceutical industry. By implementing AI, manufacturers can more deeply understand their operations and predict issues before they occur. 

Anticipating the performance of a process before it has ended can enable pharmaceutical companies to significantly improve yield output and drastically reduce manufacturing costs for any given process.

The solution also allows for a reduction in manual operations from days or weeks to minutes or hours. Importantly, Aizon’s solution can minimize batch rejection through automated deviation prediction. Manufacturers can continuously control for any potential multivariate outliers and their causes, even when inside the specification limits.

“At Aizon, we are committed to delivering compliant automation and solutions to improve yield and quality to highly regulated industries through the development of Pharma 4.0 based products that leverage AI,” said John Vitalie, CEO of Aizon. “Transforming manufacturing operations with the use of advanced analytics and AI, optimizes production and quality. Leveraging a wider variety of data and applying real-time predictive intelligence is a fundamental shift away from the way drugs have been manufactured for many years. This type of automation is enabling major performance improvement for all sizes of manufacturers and there is no technical barrier to applying data intelligence and predictability throughout the whole process to not only save time and money - but also to save more lives and improve the health of millions around the globe.”

The mission of the AI Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of AI and machine learning related categories. This year’s program attracted more than 2,950 nominations from over 18 different countries throughout the world. 

“The reality is that pharmaceutical companies have lagged behind other industries with regard to adopting new technology and manufacturing specifically - the core part of the supply chain - has remained virtually unchanged,” said James Johnson, managing director, AI Breakthrough. “By helping these companies discover hidden insights and analyze their processes through the power of AI, Aizon enables the production of drugs at higher quality while reducing time to market. Congratulations to the entire Aizon team on winning a well-deserved 2022 AI Breakthrough Award.”

Aizon is working with global leading Life Sciences organizations to set the new standard for regulated industries and their use of AI.

June 21, 2022

Aizon Launches GxP-Compliant Data Processing Solution to Accelerate Digital Transformation for Life Sciences Manufacturing

Aizon Digitize helps Life Sciences manufacturers transition from paper to digital, improving operations, reducing costs, lowering risks and increasing transparency

SAN FRANCISCO – (June 21, 2022) – Aizon announced today the launch of its new GxP-compliant data processing product, Aizon Digitize. Digitize provides Life Sciences Manufacturers with a solution to help spearhead their digital transformation, ramping up productivity and avoiding time-consuming data inputs prone to errors. 

 

Aizon Digitize automatically uploads paper records and commonly used file formats to begin the creation of an audit trail and it immediately enables tracking of changes to the data, and integrates with eBR, LIMS, QMS and Manufacturing Execution Systems (MES), to deliver powerful insights. This previously inaccessible data is now leverageable to make timely decisions to both increase productivity and decrease costs. Digitize is the first step towards realizing the full potential of applying Pharma 4.0 technologies to solve the most common to the most complex manufacturing problems.

 

The Life Sciences industry is accelerating the adoption of Pharma 4.0 technologies to address the need to increase quality and capacity, requiring a massive transformation in the way drugs and vaccines are manufactured. Additionally, intensifying competition and enhanced regulatory guidance are shifting investment priorities for pharmaceutical companies to focus on optimizing existing manufacturing processes. With approximately 30% of available data being leveraged to improve these processes, manufacturers have a tremendous opportunity to create a holistic view of their operations and shift to a predictive operation, providing much greater insight to empower the Users to make more timely and accurate decisions.

“Many pharmaceutical manufacturers still rely on manual entries and processes to perform critical tasks. This very common approach exponentially increases the risk of introducing errors and hindering their ability to optimize the entire development and manufacturing process,” said John Vitalie, CEO, Aizon. “Aizon Digitize helps Users avoid unnecessary manual entry and transfer of information which can create volumes of erroneous data resulting in increasing levels of risk. By shifting the manual workload to an automated digital process, our customers can leverage all of the valuable data trapped in paper-based records and spreadsheets. This is the on-ramp to realizing the benefits that compliant Pharma 4.0 technology can bring to any biopharma manufacturing operation.”

Moving from Paper to Digital Information

Aizon’s Digitize takes manual and spreadsheet-driven processes and allows for the digital storage and validation of the data through Optical Character Recognition (OCR) and forms-based data entry. Through digitizing data, organizations can take the first step towards the paradigm of a fully adaptive plant.

With Aizon Digitize, organizations can ingest multiple data types and safely store them in the cloud, including handwritten, PDF, and spreadsheet data. Digitize provides both customized and dynamically-built forms that enable forms-based data entry. Users receive confirmation that form entry matches expected data type, which they can save in records compliant with CFR 21 part 11.

About Aizon

Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictively insights in a GxP compliant manner with end-to-end data integrity.

April 5, 2022

Aizon Partners with TetraScience to Help Pharmaceutical Customers Increase the Speed and Efficiency of Drug Manufacturing

Partnership Demonstrates Increasing Adoption of Tetra Data to Create Unrestricted Innovation

SAN FRANCISCO – April 6, 2022 – Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, and TetraScience, the R&D Data Cloud company, announced today a partnership that will increase customers’ ability to create end-to-end data integrity and speed the delivery of drugs with improved quality and higher output.

“Aizon innovates how customers use data to achieve actionable insights within and across manufacturing sites,” says Simon Meffan-Main, Ph.D., Vice President of Product for TPN. “We are delighted to partner with them to increase operational effectiveness from development through manufacturing using Tetra Data to create data liquidity and enable Aizon’s advanced analytics.”

Pharmaceutical manufacturers are increasingly adopting advanced technologies to integrate systems where data can be analyzed by algorithms and used for critical real-time business and operational efficiencies. However, moving scientific data from development into manufacturing and integrating data produced in heterogeneous formats for advanced analytics remains an obstacle.    

Aizon uses advanced AI to provide deeper insights that inform better decision making in manufacturing across a range of applications, including predictive maintenance, bioreactor, digital twin and GxP compliant data aggregation with contextualization. The Tetra R&D Data Cloud ingests raw scientific data from disparate sources and engineers it into the industry’s only universally adoptable format, Tetra Data, which is harmonized, compliant, liquid, and actionable and can be used to accelerate scientific and operational outcomes across the pharma value chain.

“By partnering with TetraScience, we can use the data aggregation and engineering capabilities of the Tetra R&D Data Cloud so that we can help customers gain speed and insights into manufacturing processes in order to scale more quickly and with consistency.” says John Vitalie, CEO of Aizon “We are excited to partner with them, on a joint effort to bring market-leading technology that is purpose-built for the industry to our customers, for real and impactful improvements on how to create value from manufacturing and GxP data.”
“Every partner added to the Tetra Partner Network creates value for customers,” says Patrick Grady, TetraScience Chairman and CEO. “As partners and customers continue to accelerate adoption of our open platform, the entire life sciences industry works in lockstep, eliminating data silos and delivering unrestricted scientific data innovation.”

Learn more about the benefits of the Aizon and TetraScience partnership.

About TetraScience

 TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D. For more information, please visit tetrascience.com.

About Aizon

Aizon is an AI software application and solution provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.

March 15, 2022

Aizon and aggity Launch Partnership to Help Biopharmaceutical Firms Increase the Speed and Efficiency of Drug Manufacturing

Through Combined Efforts, the Partnership Will Advance Pharma 4.0 Transformation in Southern Europe

SAN FRANCISCO – (March 15, 2022) – Aizon, an enterprise AI software provider, and aggity, a Spanish firm focused on business digital transformation, announced today a partner program agreement to collaborate around accelerating digital transformation within manufacturing operations at the world’s leading pharmaceutical and biotech manufacturers.

This collaborative effort is based on Aizon’s SaaS platform leveraging Industry 4.0 technologies like artificial intelligence (AI) and machine learning to improve manufacturing operations for the biopharmaceutical industry, combined with aggity’s unique domain expertise, which combines best practices and operating models with innovative technological solutions, to optimize enterprise processes throughout.

“We are excited to partner with Aizon, a joint effort to bring market-leading technology that is purpose-built for the industry to our customers, for real and impactful improvements on how to create value from manufacturing data in GxP environments”, says Óscar Pierre, CEO and President at aggity.

Through this partnership, the Aizon AI SaaS platform will be able to successfully monitor and optimize aggity’s customers’ operations, identifying and eliminating the root causes of operational issues, enhancing operating performance – all while ensuring GxP compliance and inherent data integrity.  Members from both organizations will work side-by-side to combine aggity’s strong knowledge in digital transformation, automation, and regulations with Aizon’s big data, industry, and advanced technological experience. 

“Aizon innovates how customers use data to achieve actionable insights within and across manufacturing sites,” says Glenn Griffin, SVP Global Sales & Alliances for Aizon. “We are delighted to join forces so that pharma and biotech companies in the region can increase operational efficiencies from development through manufacturing, improve processes, and accelerate the delivery of therapeutic products.”

About aggity

aggity is a Spanish multinational specialized in digital transformation for business management. With more than 300 employees globally and a consolidated turnover forecast for 2022 of 27.2 M€, aggity has headquarters in Barcelona and Madrid (Spain), and Milan (Italy) and has a central office for Latin America in Mexico DF and subsidiaries in Argentina, Uruguay, Chile, Peru, Colombia, Venezuela and Ecuador. The company has digital transformation laboratories in Barcelona, ​​Alicante and Mexico. aggity provides solutions and services to more than 750 customers in more than 20 countries, operating in range of sectors that includes food & beverage, finance and insurance, industry, health and public administration.

About Aizon

Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.

January 24, 2022

Aizon Launches Predictive Maintenance Solution for Pharmaceutical Manufacturing

Aizon Asset Health helps pharmaceutical manufacturers and biotech companies optimize the performance of their equipment and other assets through intelligent, real-time monitoring and alerting.

SAN FRANCISCO – (January 24, 2022) – Aizon announced today the launch of its new asset monitoring application for pharmaceutical manufacturers and biotech companies. Built on Aizon’s GxP compliant AI SaaS Platform, Aizon Asset Health provides intelligent historical maintenance analysis, proactively monitors the condition of critical assets in real time, identifies potential problems and provides actionable maintenance recommendations that keep equipment up and running optimally. This data-driven maintenance approach reduces maintenance costs, eliminates unplanned downtime and optimizes product yield—unlocking the full potential of Smart Pharma Manufacturing.

Keeping manufacturing assets in effective working order can be costly and wasteful. A schedule-based approach to maintenance often results in the unnecessary repair or replacement of equipment in acceptable working conditions or conversely results in catastrophic failure of equipment due to undiagnosed issues. This can cause production disruptions, lead to product rejection, impact time to market and compromise First Time Right, that is ensuring that any procedure is performed in the right manner the first time and every time. Using advanced analytics and multivariate analysis, together with artificial intelligence, the Aizon Asset Health application further optimizes the reduction in unplanned downtime through condition-based maintenance beyond today’s industry standard – ultimately reducing maintenance expenses while improving asset reliability and performance.

“Pharmaceutical manufacturers and biotech companies are under tremendous pressure to maximize the return on investment and to reduce unplanned downtime; however, traditional schedule-based maintenance approach tends to fall short in terms of gaining control of downtime and the high costs associated with replacing equipment in an effort to achieve better performance,” said John Vitalie, CEO, Aizon. “Our Asset Health application enables our customers to harness the power of their equipment and environmental data to slash maintenance costs, optimize equipment performance, enhance product output and improve product quality.”

Intelligent, Real-Time Asset Monitoring Across Equipment and Facilities

The Aizon Asset Health application allows pharmaceutical manufacturers and biotech companies to leverage predictive power to monitor the health of assets, and—based on the prescriptive and conditional data-driven insights that the solution provides—receive advanced warnings on their conditions. These actionable insights empower operators and maintenance teams to react and intervene in real time and keep production lines up and running. A cloud native application, Asset Health can be scaled across multiple facilities and locations and provide a historical record and status of all equipment.

This allows pharmaceutical manufacturers and biotech companies to ensure complete asset integrity, maintain optimal facility conditions (such as temperature, humidity and vibrations), predict the expected lifespan of equipment and track the energy an asset has consumed and its CO2 emissions. These critical insights are consolidated on a single dashboard specifically customized to manage any organization’s unique asset maintenance needs.

“Demands on pharmaceutical manufacturing have never been higher, the Aizon Asset Health application helps manufacturers prevent unplanned downtime and maximize product quality and yield,” said Andy Alasso, SVP Product, Aizon. “Aizon Asset Health taps into real-time sensor data, consolidates it, and leverages AI to generate alarms and/or actionable insights to optimize asset performance. It’s a game changer for the industry.”

Aizon Asset Health is generally available now globally.

About Aizon

Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.

December 7, 2021

Aizon Launches a New GxP Compliant Data Aggregation Solution, Accelerating Digital Transformation for Biopharma Manufacturing

Aizon Unify helps biopharmaceutical manufacturers harmonize data to improve performance, increase production capacity, reduce operating costs and improve product quality.

SAN FRANCISCO – (December 8, 2021) – Aizon announced today the launch of its new GxP compliant data aggregation, governance, and visualization solution for pharmaceutical manufacturers. Aizon Unify provides a compliant digital platform for monitoring, analysis and optimization of all stages in the development and manufacturing processes for the biopharmaceutical industry. Ideal for organizations just starting their digital transformation journey, Aizon Unify enables seamless information sharing between people, machines and sensors—driving higher profitability through real-time analysis, greater business insights and process optimizations.

The pharmaceutical industry is undergoing a massive transformation that is impacting the way drugs and vaccines are manufactured. Increased competition and an enhanced regulatory landscape are forcing drug companies to eliminate waste, create efficiencies and optimize existing processes. Data and digital transformation are driving these initiatives—giving manufacturers unparalleled visibility into manufacturing processes. However, there are literally thousands of parameters and factors that go into making a consistent product–and these data sets are created, stored and consumed in distinct silos with little integration between them. The ability to seamlessly and efficiently capture and monitor disparate data from across the organization and turn it into actionable information is critical. Aizon Unify utilizes GxP compliant IoT software to begin collecting data within a few hours and provides data visibility and control without the need for extensive programming and months of development, helping manufacturers achieve the ‘Connected Plant.’

“Pharmaceutical manufacturers face a daunting challenge as they look to upgrade and automate the manual processes that have run their businesses for decades,” said John Vitalie, CEO, Aizon. “Manufacturers just starting their digital transformation journey first need to get access to siloed data and then combine the data to use key insights to make it actionable. Our goal at Aizon is to give them a tangible starting point to use a greater variety of data to streamline operations through automation, improve yield and enhance product quality.”

Real-Time Monitoring and Analytics in a Single Digital Dashboard

Aizon Unify aggregates data from any pharmaceutical data, system, device or sensor to consolidate, contextualize, analyze and visualize disparate data—giving operators a seamless way to bring order and intelligence to specific and complex production processes. The Aizon Unify solution automates the collection of data from all relevant areas of the manufacturing process and identifies optimization opportunities using pre-built analytical models. 

Aizon Unify leverages both historical as well as real-time data helping operators get a consolidated view of a facility or across multiple facilities.  Transparency into this data helps operators identify bottlenecks or inefficiencies, assess risk and make data-driven decisions that allow them to respond quickly to conditions in the moment. The solution includes robust security features and data validation to deliver trustworthy GxP compliance, ensuring products are safe, meet their intended use and adhere to quality standards.

“Aizon Unify can be a game changer for pharmaceutical manufacturers looking to improve operations through digital transformation,” said Andy Alasso, SVP Product, Aizon. “Breaking down existing data silos and unleashing the power of their data to inform decision making in the moment creates the business agility they need to meet today’s competitive and regulatory challenges.”

Aizon Unify is generally available now. For more details, visit https://connect.aizon.ai/Aizon-Unify.html

About Aizon

Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.